Study assesses the prevalence of complications following regular use of cannabis.
Read More »Yearly Archives: 2018
The Delayed Effect of Dietary Change on Insulin Sensitivity in Children with a Family History of Obesity
Variations in certain macronutrients may be correlated to change in insulin sensitivity/resistance.
Read More »Liraglutide Lowers Risk of Cardiovascular Events In Type 2 Diabetes
GLP-1 treatment benefits patients on statins and with varying LDL levels.
Read More »Stricter Treatment Targets for Gestational Diabetes Leads to Earlier Births, No Difference in Birth Weight
New study shows implementing tighter treatment goals for GDM does not improve birth weight in neonates, but may increase risk for earlier birth and clinician intervention.
Read More »Genetic Risk Score for Type 1 Diabetes Predicts Progression of Disease
Study focuses on score accuracy to improve prediction models for the better.
Read More »Type 2 Meds with Cardio Benefits
John S. is a 63-year-old white man with significant abdominal obesity, type 2 diabetes, hypertension, and dyslipidemia as well. On the basis of an exercise stress test, John was recently diagnosed with silent ischemia. John’s current medications include metformin, a DPP-4 inhibitor, an ACE inhibitor/HCTZ agent, a calcium channel blocker, a high-dose statin, and ezetimibe. John’s relevant physical exam and laboratory findings are as follows:
BMI: 34.8 kg/m2
Blood pressure: 140/86 mm Hg
HbA1C: 7.2%
Total cholesterol: 150 mg/dL
LDL-C: 79 mg/dL
HDL-C: 42 mg/dL
Triglycerides: 145 mg/dL
non-HDL-C: 118 mg/dL
eGFR: 65 mL/min/1.73 m2
ACR: 100 mg albumin/g creatinine
Which statement best describes the evidence supporting cardiovascular benefits of the antihyperglycemic agents available to treat John’s type 2 diabetes?
A. Further glucose reduction using any available agent should have similar cardiovascular disease benefit.
B. Thiazolidinediones increase the risk of heart failure and myocardial infarction in patients with type 2 diabetes.
C. Two approved GLP-1 receptor agonists have been shown to reduce mortality in patients with type 2 diabetes and cardiovascular disease.
D. Both GLP-1 receptor agonists and SGLT2 inhibitors affect cardiovascular risk through the same physiologic mechanisms.
Follow the link for the answer.
Read More »Smart Pumps
With all the new insulin pump technology, do you feel that more patients, with either type 1 or type 2 using insulin, will move towards the smart pump rather than an insulin pump? Follow the link to see how you compare to your colleagues.
Read More »Fear Impacts Quality of Life for Young Adults With Type 1 Diabetes
Young adults cite fear of complications, burden of disease management, impact on family and job
Read More »Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
Significant association for men, with positive but not statistically significant link seen for women
Read More »Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality
Prediction independent of traditional risk factors such as MetS, glucose, HbA1c in general population
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.